CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof

This patent covers a therapeutic composition of gene-edited blood stem cells for treating sickle cell disease. In plain English, claim 1 defines a single dose of CD34+ human hematopoietic stem and progenitor cells (hHSPCs) carrying a CRISPR-Cas9 edit at a specific genomic target — the +58 DNase I hypersensitive site within the erythroid lineage-specific enhancer of the BCL11A gene. Disrupting this enhancer site reactivates fetal hemoglobin, which compensates for defective adult hemoglobin. The claim is unusually concrete: the edit must be made by delivering a Cas9 endonuclease plus a guide RNA of SEQ ID NO: 1 or SEQ ID NO: 2; the dose must contain a minimum of 3×10⁶ CD34+ cells per kg; and the dose must be an "effective amount to result in an absence of vaso-occlusive crises (VOCs) for at least 12 months after administration." That clinical-outcome limitation — tying the claim to a defined durable therapeutic response — is the distinctive feature, with dependent claims adding cryopreservation-medium formulation details (serum-free, 5% DMSO, dextran-40).

The patent is assigned to Vertex Pharmaceuticals Incorporated, with a large named-inventor team (Morawa, Chakraborty, Lundberg, Ho, Sandler, Eustace, Rossert, Kauffman). It was granted in 2024. The family is sizeable — 15 members across 13 countries — indicating aggressive international prosecution consistent with a globally commercialized product. Forward citations stand at 0, which is expected for a 2024 grant and reflects publication lag rather than low significance; for a strategic, product-anchoring filing, citation-weighted ranking systematically under-rewards this kind of late-stage claim.

Where this patent stands: This is a commercially anchored, late-stage filing rather than a foundational platform patent. The underlying CRISPR-Cas9 mechanism and the BCL11A enhancer target were established earlier (by the Broad Institute, Harvard, and Children's Medical Center; see below); Vertex's contribution here is the specific, clinically validated product configuration — the exact guide RNAs, the minimum dose, and the durable VOC-free outcome. This claim profile corresponds directly to exa-cel / Casgevy, the BCL11A-edited autologous cell therapy developed by Vertex with CRISPR Therapeutics. As such it functions as a product-protecting claim layered on top of upstream tool and target IP, sitting within a tight portfolio of related Vertex filings on hemoglobinopathy treatment.

The surrounding space is densely clustered and academically anchored. The genetic-engineering area dominates the corpus context: Genetic Engineering (C12N) runs at 44.7× the corpus baseline, the strongest concentration here and clear evidence the field is tightly clustered around CRISPR-based cell therapy, alongside Pharmaceutical Preparations (A61K) at 19.1× and Therapeutic Drug Activity (A61P) at 20.4×. By citation impact the leaders are foundational academic and institutional players — The Broad Institute (3 patents, 1,396 citations), MIT (448), and Harvard (3 patents, 247) — reflecting their ownership of core CRISPR platform IP rather than hemoglobinopathy products specifically. With Broad, MIT, Harvard, Fred Hutchinson, and Johns Hopkins all in the top 10, the citation leaderboard is heavily university/institute-weighted, which means licensing of upstream tools matters as much as freedom-to-operate when navigating this space. Notably, Vertex dominates the nearest patents to the subject — it is the assignee on 4 of the closest 5 results — but it does not appear on the citation-ranked TOP_ASSIGNEES list, because its filings are recent and lightly cited.

Closest related filings:

• US-10738305-B2 — Materials and methods for treatment of hemoglobinopathies (Vertex · 8 citations · 26-member family). An earlier, broader Vertex grant on the same therapeutic program; the subject patent narrows toward a specific dosed, outcome-defined product.
• US-9822355-B2 — Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction (Children's Medical Center Corporation · 5 citations · 49-member family). Establishes the BCL11A erythroid enhancer as the editing target — the biological foundation the subject patent's specific +58 DHS guide RNAs build upon.
• US-2015176013-A1 — Therapeutic uses of genome editing with CRISPR/Cas systems (Harvard · 230 citations · 18-member family), and US-8795965-B2 — CRISPR-Cas component systems (Broad Institute · 774 citations · 73-member family). These are the high-citation upstream platform filings covering the CRISPR-Cas9 tool itself; the subject patent applies that tool to a defined clinical indication.
• US-2019201553-A1 — Materials and methods for treatment of hemoglobinopathies (CRISPR Therapeutics AG · 5 citations · 38-member family). From Vertex's development partner, covering the same therapeutic class and closely allied to the subject portfolio.
• US-2024335476-A1 — Systems and methods for the treatment of hemoglob